论文部分内容阅读
目前,临床已广泛应用重组人粒-巨噬细胞集落刺激因子(rhGM-CSF)等髓系生长刺激因子,以促进移植物的植入并减少化疗副作用。但人们仍对其是否有后期毒性,如导致移植失败及治疗相关白血病或促使复发等存有疑虑。为此,作者对128例自体骨髓移植(ABMT)后的患者作了rhGM-CSF后期
At present, myeloid growth stimulating factors such as recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) have been widely used clinically to promote the implantation of implants and reduce the side effects of chemotherapy. However, there is still some concern about whether it has late toxicity, such as failure of transplant, treatment-related leukemia or relapse. To this end, the authors of 128 patients after autologous bone marrow transplantation (ABMT) made rhGM-CSF late